Although the significant parameters predicting IDH mutation confirmed the diagnostic accuracy in another validation dataset, such validation was impossible since glioma is not a common disease, particularly non-contrast-enhanced glioblastoma (IDH-wt). The gene discussed is IDH2; the disease is central nervous system cancer.